Roche: positive data for Vabysmo in RVO
(CercleFinance.com) - Roche announces initial positive long-term results from the worldwide Phase III BALATON and COMINO studies, evaluating extended treatment intervals with Vabysmo in macular edema due to retinal vein occlusion (RVO).
Roche says that its Vabysmo maintained vision improvements with extended treatment intervals of up to four months, with a safety profile consistent with previous studies.
RVO affects 28 million people worldwide and, if approved, this would be the third indication for Vabysmo in addition to neovascular or "wet" age-related macular degeneration and diabetic macular edema.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Roche says that its Vabysmo maintained vision improvements with extended treatment intervals of up to four months, with a safety profile consistent with previous studies.
RVO affects 28 million people worldwide and, if approved, this would be the third indication for Vabysmo in addition to neovascular or "wet" age-related macular degeneration and diabetic macular edema.
Copyright (c) 2023 CercleFinance.com. All rights reserved.